<DOC>
	<DOCNO>NCT00941915</DOCNO>
	<brief_summary>The purpose study evaluate incidence urinary gastrointestinal acute late side effect patient treat stereotactic body radiotherapy ( SBRT ) prostate . Stereotactic radiation therapy give five treatment 2-3 week period . The prostate localize plan reoptimized needed prior treatment .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy ( SBRT ) Prostate Cancer</brief_title>
	<detailed_description>This protocol require radiation treatment perform stereotactic technique use 3-D coordinate system define implanted transponder ( i.e . Calypso ) use ExacTrac system and/or use cone-beam CT ( CBCT ) fiducial marker .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis adenocarcinoma prostate within 365 day study enrollment History/physical examination digital rectal examination prostate within 8 week prior study enrollment Gleason score less equal 7 Clinical Stage T1T2c PSA less = 15 ng/ml prior start therapy Gleason &lt; = 6 less = 10 ng/ml prior start therapy Gleason = 7 Zubrod Performance Status 01 Age &gt; 40 Prior concurrent invasive malignancy ( except nonmelanomatous skin cancer ) lymphomatous/hematogenous malignancy unless continually disease free minimum 5 year . ( Carcinoma situ bladder oral cavity permissible ) Evidence distant metastasis Regional lymph node involvement Significant urinary obstruction Estimated prostate gland &gt; 100 gram Previous radical surgery ( prostatectomy ) cryosurgery prostate cancer Previous pelvic irradiation , prostate brachytherapy , bilateral orchiectomy Previous hormonal therapy , LHRH agonists ( e.g . goserelin , leuprolide ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , DES ) , surgical castration ( bilateral orchiectomy ) plan concurrent androgen deprivation therapy Previous concurrent cytotoxic chemotherapy prostate cancer Prosthetic implant pelvic region contain metal conductive material ( e.g. , artificial hip ) . Severe , active comorbidity</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CaP</keyword>
	<keyword>SBRT</keyword>
	<keyword>Prostate</keyword>
	<keyword>ExacTrac</keyword>
	<keyword>Calypso</keyword>
	<keyword>IMRT</keyword>
	<keyword>Radiation</keyword>
	<keyword>Cancer Prostate</keyword>
	<keyword>Prostatic Neoplasms</keyword>
</DOC>